ERBB2 and breast carcinoma: In HER2-positive advanced breast cancer, studies have shown that after failure of trastuzumab-containing therapy, the continuing of trastuzumab beyond progression in combination with another regimen of chemotherapy was associated with improvement of clinical outcomes [19, 20].